Global Medical REIT (XRN) Financials

Global Medical REIT (NYSE: XRN) showed a mixed but overall pressured financial profile in Q1 2026. The company remained profitable on a pre-dividend basis and generated solid operating cash flow, but common shareholders still saw a loss after preferred dividends. Compared with prior quarters, profitability and cash generation improved from the weak Q4 2025 period, though leverage and interest costs remain significant.

• Operating cash flow rebounded: Net cash from operating activities was $13.4 million in Q1 2026, up from $2.0 million in Q4 2025 and $17.6 million in Q3 2025. That suggests the underlying business is still producing cash.
• Pre-tax income turned positive: Q1 2026 pre-tax income was $1.7 million, improving sharply from a $12.0 million pre-tax loss in Q4 2025.
• Net income improved sequentially: Consolidated net income rose to $1.65 million from a $6.15 million loss in Q4 2025.
• Cash balance improved versus late 2025: Cash and equivalents totaled $8.2 million at March 31, 2026, up from $7.1 million at the end of Q3 2025.
• Debt decreased modestly from the prior quarter: Total liabilities fell to $717.4 million from $767.4 million at the end of Q3 2025, indicating some balance-sheet improvement.
• Revenue remains dependent on non-interest income: Q1 2026 total revenue was $30.8 million, driven largely by $38.1 million of non-interest income, while net interest income remained negative.
• Interest costs are still heavy: The company recorded $7.2 million of interest expense in Q1 2026 and paid $6.5 million in cash interest, which continues to pressure earnings.
• Dividend burden is meaningful: Preferred stock dividends were $2.5 million in Q1 2026, which helped push common shareholder earnings back into the red.
• Share count was steady: Weighted average diluted shares were 13.2 million, so the quarter’s EPS movement was driven more by operating results than dilution.
• Common shareholders still posted a loss: Net income attributable to common shareholders was -$749,000 in Q1 2026, even though consolidated net income was positive.
• Debt load remains high: Short-term debt alone was $662.3 million, and total liabilities were more than 1.3x quarterly revenue on an annualized basis.
• Large quarterly investment spending: The company used $9.8 million in investing cash flow, including $7.2 million for investment securities and $2.1 million for property and equipment.
• Balance sheet remains asset-heavy with limited liquidity: Cash and equivalents were only a small fraction of total assets of $1.24 billion, leaving limited cushion if cash flow weakens.

Trend takeaway: Over the last several years, Global Medical REIT has generally been able to generate operating cash flow, but earnings have been volatile and often pressured by interest expense, preferred dividends, and changes in investment gains or losses. The latest quarter shows a recovery from Q4 2025, but the business still appears highly leveraged and sensitive to financing costs.

Bottom line: For retail investors, XRN looks like a company with decent cash generation but limited room for error. The near-term story is improvement in profitability, but the balance sheet and financing burden remain the key risks to watch.